Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
Am J Ophthalmol ; 132(5): 700-10, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11704031

ABSTRACT

PURPOSE: Cytomegalovirus retinitis is the most common intraocular infection in patients with acquired immunodeficiency syndrome (AIDS). With prolonged suppressive anticytomegalovirus maintenance therapy, resistance occurs in over 25% of patients. We evaluated longitudinal changes in the cytomegalovirus genotype in patients with cytomegalovirus retinitis who developed ganciclovir resistance that was demonstrated in either the blood or urine. METHODS: Patients with AIDS and previously untreated cytomegalovirus retinitis were followed prospectively for the occurrence of resistance while on treatment. Blood and urine specimens were obtained periodically for cytomegalovirus culture according to a predetermined schedule. Positive isolates were tested for phenotypic susceptibility and for mutations in the UL97 and UL54 genes. RESULTS: A mutation conferring resistance to ganciclovir in either the UL97 or UL54 gene was detected in 18 patients. In general, patients with a genotypically resistant virus developed increasing phenotypic resistance over time. There was a suggestion that unless therapy was changed, UL97 mutations tended to persist. In seven of eight patients, the mutations identified in isolates from the blood and urine were identical. In selected patients, there was a suggestion that a mixed population of cytomegalovirus might be present. Progression of the retinitis in an involved eye (15 of 18), contralateral eye retinitis (10 of 11), and extraocular cytomegalovirus disease (5 of 18) occurred commonly among patients with resistant virus. CONCLUSION: Resistance-conferring mutations in the cytomegalovirus genome emerge and may persist when the selective pressure for resistance is maintained. Some patients appear to harbor complex subpopulations of virus with different mutations and different levels of phenotypic resistance. Changes in therapy may result in a shift in virus population and changes in the cytomegalovirus genotype identified.


Subject(s)
AIDS-Related Opportunistic Infections/virology , Antiviral Agents/pharmacology , Cytomegalovirus Retinitis/virology , Cytomegalovirus/drug effects , Ganciclovir/pharmacology , Mutation , Viral Proteins , Adult , Aged , Blood/virology , Cohort Studies , Cytomegalovirus/genetics , Cytomegalovirus/isolation & purification , DNA, Viral/analysis , DNA-Directed DNA Polymerase/genetics , Drug Resistance, Microbial , Female , Genotype , Humans , Male , Middle Aged , Phosphotransferases (Alcohol Group Acceptor)/genetics , Prospective Studies , Urine/virology
2.
Clin Diagn Lab Immunol ; 8(6): 1279-81, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11687477

ABSTRACT

The average 50% inhibitory concentration (IC(50)) values for AD169 were 0.22 +/- 0.09 microM 1263W94 and 5.36 +/- 0.12 microM ganciclovir. For 35 human cytomegalovirus (HCMV) clinical isolates the average IC(50) was 0.42 +/- 0.09 microM 1263W94, and for 26 ganciclovir-susceptible HCMV clinical isolates the average IC(50) was 3.78 +/- 1.62 microM ganciclovir. Nine HCMV clinical isolates that were resistant to ganciclovir were completely susceptible to 1263W94.


Subject(s)
Anti-HIV Agents/pharmacology , Antiviral Agents/pharmacology , Benzimidazoles/pharmacology , Cytomegalovirus/drug effects , Ganciclovir/pharmacology , Ribonucleosides/pharmacology , Cytomegalovirus/genetics , DNA, Viral/analysis , Fibroblasts/virology , Flow Cytometry , Humans , Inhibitory Concentration 50 , Nucleic Acid Hybridization , Viral Plaque Assay
3.
J Infect Dis ; 183(2): 333-337, 2001 Jan 15.
Article in English | MEDLINE | ID: mdl-11120934

ABSTRACT

Cytomegalovirus (CMV) retinitis is among the most common opportunistic infections in patients with acquired immunodeficiency syndrome. In a prospective study of 210 patients with CMV retinitis, 26 were identified as having either a phenotypic or a genotypic ganciclovir-resistant isolate from either blood or urine cultures. For blood culture isolates with an IC(50) >6.0 microm for ganciclovir, the sensitivity and specificity for detecting a UL97 mutation were 95% and 98%, respectively, whereas for an IC(50) >8.0 microM they were 79% and 99%, respectively. Although there were trade-offs between the 2 thresholds for blood culture isolates, for urine culture isolates an IC(50) >8.0 microM appeared to be better at identifying genotypic resistance. UL97 mutations identified in both the blood and urine cultures of individual patients were identical in 87.5% of cases. High-level ganciclovir resistance (IC(50), >30 microM) typically, but not invariably, was associated with a mutation in both the UL97 and UL54 genes.


Subject(s)
AIDS-Related Opportunistic Infections/virology , Antiviral Agents/pharmacology , Cytomegalovirus Retinitis/virology , Cytomegalovirus/drug effects , Ganciclovir/pharmacology , Mutation , Viral Proteins , Adult , Aged , Blood/virology , Cohort Studies , Cytomegalovirus/genetics , Cytomegalovirus/isolation & purification , DNA-Directed DNA Polymerase/genetics , Drug Resistance, Microbial/genetics , Female , Genotype , Humans , Male , Middle Aged , Phenotype , Phosphotransferases (Alcohol Group Acceptor)/genetics , Prospective Studies , Urine/virology
4.
Article in English | MEDLINE | ID: mdl-10772705

ABSTRACT

A series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94) were synthesized and evaluated for activity against human cytomegalovirus (HCMV) and for cytotoxicity. The 2-substituents in the benzimidazole moiety correspond to those that were used in the 1263W94 series. In general, as was found in the 1263W94 series, cyclic and branched alkylamino groups were needed for potent activity against HCMV. Three analogues 3a, 3b and 3d were as potent as 1263W94. Further evaluation of two analogues, 3a and 3b, suggested that these 2'-deoxy analogues may act via a novel mechanism of action similar to that of 1263W94. These 2'-deoxy analogues generally lacked cytotoxicity in vitro. Pharmacokinetic parameters in mice and protein binding properties of 3a were quite similar to 1263W94. However, the oral bioavailability of 3a was only half of that observed for 1263W94.


Subject(s)
Antiviral Agents/chemical synthesis , Benzimidazoles/chemical synthesis , Cytomegalovirus/drug effects , Ribonucleosides/chemical synthesis , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacokinetics , Antiviral Agents/pharmacology , Benzimidazoles/chemistry , Benzimidazoles/pharmacokinetics , Benzimidazoles/pharmacology , Biological Availability , Cells, Cultured , Humans , Magnetic Resonance Spectroscopy , Male , Mice , Mice, Inbred Strains , Ribonucleosides/chemistry , Ribonucleosides/pharmacokinetics , Ribonucleosides/pharmacology
5.
Article in English | MEDLINE | ID: mdl-10772719

ABSTRACT

A racemic mixture of ganciclovir phosphonate was resolved by stereoselective phosphorylation using GMP kinase. The R-enantiomer of ganciclovir phosphonate was active against human cytomegalovirus but the S-enantiomer was less active. We show that enantiomeric selectivity of antiviral for ganciclovir phosphonate was conferred by stereoselective phosphorylations by mammalian enzymes, not by stereoselective inhibition of DNA polymerase from human cytomegalovirus.


Subject(s)
Antiviral Agents/chemistry , Cytomegalovirus/drug effects , Ganciclovir/analogs & derivatives , Nucleoside-Phosphate Kinase/chemistry , Antiviral Agents/isolation & purification , Antiviral Agents/metabolism , Antiviral Agents/pharmacology , Cell Line , Ganciclovir/chemistry , Ganciclovir/isolation & purification , Ganciclovir/metabolism , Ganciclovir/pharmacology , Guanylate Kinases , Humans , Nucleic Acid Synthesis Inhibitors , Nucleoside-Phosphate Kinase/metabolism , Phosphorylation , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Stereoisomerism , Structure-Activity Relationship
6.
Antivir Chem Chemother ; 11(5): 349-52, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11142634

ABSTRACT

The AD169 strain of human cytomegalovirus was approximately twofold more sensitive to polyhalogenated benzimidazole ribonucleosides than Towne strain. Sequence differences between the two strains have been identified in genes UL51, UL52, UL56, UL77, UL89 and UL104. Because these genes are involved in cleavage and packaging of viral DNA and the benzimidazole ribonucleosides inhibit this process, these sequence differences may be involved in the difference in drug sensitivity.


Subject(s)
Benzimidazoles/chemistry , Cytomegalovirus/physiology , Ribonucleosides/pharmacology , Virus Assembly/genetics , Cytomegalovirus/genetics , Genes, Viral , Molecular Sequence Data , Ribonucleosides/chemistry
7.
J Virol ; 73(9): 7271-7, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10438815

ABSTRACT

Although a number of antiviral drugs inhibit replication of Epstein-Barr virus (EBV) in cell culture, and acyclovir (ACV) suppresses replication in vivo, currently available drugs have not proven effective for treatment of EBV-associated diseases other than oral hairy leukoplakia. Benzimidazole riboside compounds represent a new class of antiviral compounds that are potent inhibitors of human cytomegalovirus (HCMV) replication but not of other herpesviruses. Here we characterize the effects of two compounds in this class against lytic replication of EBV induced in a Burkitt lymphoma cell line latently infected with EBV. We analyzed linear forms of EBV genomes, indicative of lytic replication, and episomal forms present in latently infected cells by terminal probe analysis followed by Southern blot hybridization as well as the high-molecular-weight unprocessed viral DNA by pulsed-field gel electrophoresis. D-Ribofuranosyl benzimidazole compounds that act as inhibitors of HCMV DNA maturation, including BDCRB (5, 6-dichloro-2-bromo-1-beta-D-ribofuranosyl-1H-benzimidazole), did not affect the accumulation of high-molecular-weight or monomeric forms of EBV DNA in the induced cells. In contrast, the generation of linear EBV DNA as well as precursor viral DNA was sensitive to the L-riboside 1263W94 [5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole]. The 50% inhibitory concentration range for 1263W94 was 0.15 to 1. 1 microM, compared with 10 microM for ACV. Thus, 1263W94 is a potent inhibitor of EBV. In addition, 1263W94 inhibited the phosphorylation and the accumulation of the essential EBV replicative cofactor, early antigen D.


Subject(s)
Antiviral Agents/pharmacology , Benzimidazoles/pharmacology , Dichlororibofuranosylbenzimidazole/pharmacology , Herpesvirus 4, Human/drug effects , Ribonucleosides/pharmacology , Virus Replication/drug effects , Acyclovir/pharmacology , Antigens, Viral/genetics , Antigens, Viral/metabolism , Cell Line , Dichlororibofuranosylbenzimidazole/chemistry , Herpesvirus 4, Human/physiology , Humans , Phosphorylation/drug effects , Transcription, Genetic/drug effects
8.
Nucleosides Nucleotides ; 18(4-5): 509-19, 1999.
Article in English | MEDLINE | ID: mdl-10432642

ABSTRACT

The potent activity of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole (TCRB) against Human Cytomegalovirus with the concomitant low cellular toxicity at concentrations that inhibit viral growth prompted considerable interest in this research area. This interest was moderated by the pharmacokinetic studies of TCRB in rats and monkeys that revealed the instability of TCRB in vivo. These studies suggested that the instability was due to a cleavage of the glycosidic bond in vivo which released the heterocycle (2,5,6-trichlorobenzimidazole) into the bloodstream. This prompted us to initiate synthetic studies designed to increase the stability of the glycosidic bond of TCRB and BDCRB. Several synthetic approaches to address this and other problems are presented.


Subject(s)
Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Cytomegalovirus/drug effects , Ribonucleosides/chemistry , Ribonucleosides/pharmacology , Animals , Haplorhini , Microbial Sensitivity Tests , Rats
9.
Antimicrob Agents Chemother ; 43(8): 1941-6, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10428917

ABSTRACT

Acyclovir (ACV) has shown efficacy in the prophylactic suppression of human cytomegalovirus (HCMV) reactivation in immunocompromised renal transplant patients without the toxicity associated with ganciclovir (GCV). The HCMV UL97 gene product, a protein kinase, is responsible for the phosphorylation of GCV in HCMV-infected cells. This report provides evidence for the phosphorylation of ACV by UL97. Anabolism studies with the HCMV wild-type strain AD169 and with recombinant mutants derived from marker transfer experiments performed by using mutant UL97 DNA from both clinical isolates and a laboratory-derived strain resistant to GCV showed that mutations in the UL97 gene cripple the ability of recombinant virus-infected cells to anabolize both GCV and ACV. These mutant UL97 recombinant viruses were less susceptible to both GCV and ACV than was the wild-type strain. A recombinant herpes simplex virus type 1 strain, in which the thymidine kinase gene is deleted and the UL13 gene is replaced with the HCMV UL97 gene, was able to induce the phosphorylation of ACV in infected cells. Finally, purified UL97 phosphorylated both GCV and ACV to their monophosphates. Our results indicate that UL97 promotes the selective activity of ACV against HCMV.


Subject(s)
Acyclovir/pharmacokinetics , Antiviral Agents/pharmacokinetics , Cytomegalovirus/enzymology , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Acyclovir/metabolism , Acyclovir/pharmacology , Animals , Antiviral Agents/metabolism , Antiviral Agents/pharmacology , Chlorocebus aethiops , Cytomegalovirus/drug effects , Cytomegalovirus/genetics , Cytomegalovirus/metabolism , Ganciclovir/pharmacokinetics , Ganciclovir/pharmacology , Herpesvirus 1, Human/drug effects , Herpesvirus 1, Human/enzymology , Herpesvirus 1, Human/genetics , Humans , Microbial Sensitivity Tests , Mutation , Phosphorylation , Vero Cells
11.
J Virol ; 72(6): 4721-8, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9573236

ABSTRACT

2,5,6-Trichloro-1-beta-D-ribofuranosyl benzimidazole (TCRB) is a potent and selective inhibitor of human cytomegalovirus (HCMV) replication. TCRB acts via a novel mechanism involving inhibition of viral DNA processing and packaging. Resistance to the 2-bromo analog (BDCRB) has been mapped to the UL89 open reading frame (ORF), and this gene product was proposed as the viral target of the benzimidazole nucleosides. In this study, we report the independent isolation of virus that is 20- to 30-fold resistant to TCRB (isolate C4) and the characterization of the virus. The six ORFs known to be essential for viral DNA cleavage and packaging (UL51, UL52, UL56, UL77, UL89, and UL104) were sequenced from wild-type HCMV, strain Towne, and from isolate C4. Mutations were identified in UL89 (D344E) and in UL56 (Q204R). The mutation in UL89 was identical to that previously reported for virus resistant to BDCRB, but the mutation in UL56 is novel. Marker transfer analysis demonstrated that each of these mutations individually caused approximately 10-fold resistance to the benzimidazoles and that the combination of both mutations caused approximately 30-fold resistance. The rate and extent of replication of the mutants was the same as for wild-type virus, but the viruses were less sensitive to inhibition of DNA cleavage by TCRB. Mapping of resistance to UL56 supports and extends recent work showing that UL56 codes for a packaging motif binding protein which also has specific nuclease activity (E. Bogner et al., J. Virol. 72:2259-2264, 1998). Resistance which maps to two different genes suggests that their putative proteins interact and/or that either or both have a benzimidazole ribonucleoside binding site. The results also suggest that the gene products of UL89 and UL56 may be antiviral drug targets.


Subject(s)
Antiviral Agents/pharmacology , Benzimidazoles/pharmacology , Cytomegalovirus Infections/virology , Cytomegalovirus/drug effects , Cytomegalovirus/genetics , Drug Resistance, Microbial/genetics , Genes, Viral , Ribonucleosides/pharmacology , Amino Acid Sequence , Cell Line , Chromosome Mapping , Cytomegalovirus Infections/drug therapy , Humans , Molecular Sequence Data , Open Reading Frames/genetics
12.
Antimicrob Agents Chemother ; 42(2): 444-6, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9527804

ABSTRACT

Two ganciclovir (GCV)-resistant human cytomegalovirus (HCMV) strains recovered from an AIDS patient (strain VR4990) and a heart transplant recipient (strain VR5474) showed a Cys607-->Tyr change in the UL97-encoded phosphotransferase. No amino acid substitutions were observed in the viral DNA polymerase. Marker transfer experiments showed marked reduction in GCV phosphorylation and drug susceptibility of the recombinant HCMV strain VR4990rec2-1-1. These results further extend the region of the carboxy-terminal domain of the UL97 phosphotransferase involved in GCV substrate recognition.


Subject(s)
AIDS-Related Opportunistic Infections/virology , Antiviral Agents/pharmacology , Cytomegalovirus/drug effects , Ganciclovir/pharmacology , Phosphotransferases (Alcohol Group Acceptor)/genetics , Cytomegalovirus/genetics , Cytomegalovirus/isolation & purification , Drug Resistance, Microbial/genetics , Heart Transplantation , Humans , Immunocompromised Host
14.
J Virol ; 72(1): 717-25, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9420278

ABSTRACT

2-Bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole (BDCRB) is a member of a new class of benzimidazole ribonucleosides which inhibit human cytomegalovirus (HCMV) late in the replication cycle without inhibiting viral DNA synthesis. We show here that polygenomic concatemeric HCMV DNA does not mature to unit genome length in the presence of BDCRB. To discover the locus of action, virus resistant to BDCRB was selected by serial passage in the presence of the compound. Genetic mapping experiments with BDCRB-resistant virus demonstrated that the resistance phenotype mapped to one amino acid (Asp344Glu; low resistance) or two amino acids (Asp344Glu and Ala355Thr; high resistance) within the product of exon 2 of the HCMV U(L)89 open reading frame. The HCMV U(L)89 open reading frame and its homologs are among the most conserved open reading frames in the herpesviruses, and their products have sequence similarities to a known ATP-dependent endonuclease from the double-stranded DNA bacteriophage T4. These findings strongly suggest that BDCRB prevents viral DNA maturation by interacting with a U(L)89 gene product and that the U(L)89 open reading frame may encode an endonucleolytic subunit of the putative HCMV terminase. Further, since mammalian cell DNA replication does not involve a DNA maturation step, compounds which inhibit viral DNA maturation should be selective and safe.


Subject(s)
Antiviral Agents/pharmacology , Benzimidazoles/pharmacology , Cytomegalovirus/drug effects , Cytomegalovirus/genetics , DNA, Viral/biosynthesis , Ribonucleosides/pharmacology , Viral Proteins/genetics , Viral Proteins/metabolism , Amino Acid Sequence , Base Sequence , Cell Line , Chromosome Mapping , Cytomegalovirus/physiology , DNA Primers/genetics , DNA Replication/drug effects , Drug Resistance, Microbial/genetics , Genes, Viral , Humans , Molecular Sequence Data , Open Reading Frames , Phenotype , Protein Biosynthesis/drug effects , Transcription, Genetic/drug effects , Virus Replication/drug effects
15.
J Virol ; 71(1): 405-11, 1997 Jan.
Article in English | MEDLINE | ID: mdl-8985364

ABSTRACT

The product of the human cytomegalovirus (CMV) UL97 gene, which controls ganciclovir phosphorylation in virus-infected cells, is homologous to known protein kinases but diverges from them at a number of positions that are functionally important. To investigate UL97, we raised an antibody against it and overexpressed it in baculovirus-infected insect cells. Recombinant baculovirus expressing full-length UL97 directed the phosphorylation of ganciclovir in insect cells, which was abolished by a four-codon deletion that confers ganciclovir resistance to CMV. When incubated with [gamma-32P]ATP, full-length UL97 was phosphorylated on serine and threonine residues. Phosphorylation was severely impaired by a point mutation that alters lysine-355 in a motif that aligns with subdomain II of protein kinases. However, phosphorylation was impaired much less severely by the four-codon deletion. A UL97 fusion protein expressed from recombinant baculovirus was purified to near homogeneity. It too was phosphorylated upon incubation with [gamma-32P]ATP in vitro. This phosphorylation, which was abolished by the lysine 355 mutation, was optimal at high NaCl and high pH. The activity required either Mn2+ or Mg2+, with a preference for Mn2+, and utilized either ATP or GTP as a phosphate donor, with Kms of 2 and 4 microM, respectively. The phosphorylation rate was first order with protein concentration, consistent with autophosphorylation. These data strongly argue that UL97 is a serine/threonine protein kinase that autophosphorylates and suggest that the four-codon deletion affects its substrate specificity.


Subject(s)
Cytomegalovirus/enzymology , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Protein Serine-Threonine Kinases/metabolism , Serine/metabolism , Threonine/metabolism , Animals , Cell Line , Ganciclovir/metabolism , Glutathione Transferase/genetics , Humans , Phosphorylation , Phosphotransferases (Alcohol Group Acceptor)/genetics , Phosphotransferases (Alcohol Group Acceptor)/isolation & purification , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/isolation & purification , Rabbits , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolism , Sequence Deletion , Spodoptera/cytology
16.
J Virol ; 70(3): 1390-5, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8627655

ABSTRACT

Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A. Sarasini, F. Baldanti, M. Furione, E. Percivalle, R. Brerra, M. Barbi, and G. Gerna, J. Med. Virol., 47:237-244, 1995). We previously demonstrated that the three strains were genetically unrelated and that each of them was present as a single viral population in vivo. Thus, in each of the three cases, a single viral strain was resistant to both GCV and PFA. In the present paper, we report the characterization of the molecular bases of the double resistance and demonstrate that the PFA resistance is associated with a slower replication of HCMV strains in cell cultures. Sequencing of the UL97 and UL54 genes, GCV anabolism assays, and marker transfer experiments showed that GCV resistance was due to single amino acid changes in the UL97 gene product (VR4760, Met-460 --> Ile; VR4955, Ala-594 --> Val; VR5120, Leu595 --> Ser), while single amino acid changes in domain II of the DNA polymerase (VR4760 and VR5120, Val-715 --> Met; VR4955, Thr-700 --> Ala) were responsible for both the PFA resistance and the slow-growth phenotype. Thus, in these three cases, double resistance to GCV and PFA was not due to a single mutation conferring cross-resistance or to the presence of a mixture of strains with different drug susceptibilities. The HCMV DNA polymerase recombinant strains carrying the mutations conferring PFA resistance were sensitive to GCV and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). In addition, the same UL54 mutations were responsible for the slow growth of the clinical isolates, since the recombinant strains showed a marked delay in immediate-early antigen plaque formation and a reduction of infectious virus yield compared with AD169, from which they were derived. These results may have some important implications for the successful isolation, propagation, and characterization of PFA-resistant strains from clinical samples containing mixed viral populations.


Subject(s)
AIDS-Related Opportunistic Infections/virology , Cytomegalovirus Infections/virology , Cytomegalovirus/drug effects , DNA-Directed DNA Polymerase/physiology , Foscarnet/pharmacology , Ganciclovir/pharmacology , Phosphotransferases (Alcohol Group Acceptor)/physiology , Amino Acid Sequence , Base Sequence , Cytomegalovirus/enzymology , Cytomegalovirus/genetics , Cytomegalovirus Infections/complications , DNA-Directed DNA Polymerase/genetics , Drug Resistance, Microbial/genetics , Drug Resistance, Multiple/genetics , Humans , Molecular Sequence Data , Mutation , Phenotype , Phosphorylation , Phosphotransferases (Alcohol Group Acceptor)/genetics
18.
Antimicrob Agents Chemother ; 39(5): 1204-5, 1995 May.
Article in English | MEDLINE | ID: mdl-7625819

ABSTRACT

Characterization of a ganciclovir-resistant cytomegalovirus strain from a patient with AIDS showed a histidine-to-glutamine change at residue 520 of UL97 (Q520 mutation). In anabolism studies, Q520 was associated with impaired phosphorylation of ganciclovir. Transfer of Q520 to a recombinant virus resulted in a ganciclovir-resistant phenotype.


Subject(s)
Cytomegalovirus/drug effects , Cytomegalovirus/genetics , Ganciclovir/pharmacology , AIDS-Related Opportunistic Infections/microbiology , Base Sequence , Drug Resistance, Microbial , Glutamine/metabolism , Histidine/metabolism , Humans , Molecular Sequence Data , Mutation/genetics , Phenotype , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...